Long-Term Studies Supporting No Increased Stillbirth Risk with COVID-19 and Tdap Vaccination in Pregnancy
The moderate-strength evidence for no increased stillbirth risk comes from large population-based cohort studies and matched case-control analyses with follow-up through delivery, particularly the Vaccine Safety Datalink study of 276 confirmed stillbirths matched to 822 live births 1, and a multicenter Australian cohort of over 32,000 births 2.
Key Evidence for COVID-19 Vaccination
The strongest evidence comes from the 2024 Vaccine Safety Datalink (VSD) matched case-control study 1, which represents the most rigorous U.S. analysis to date:
- No association between COVID-19 vaccination during pregnancy and stillbirth (38.4% stillbirths vs 39.3% live births in vaccinated individuals, adjusted OR 1.02,95% CI 0.76-1.37)
- Analysis included 276 confirmed antepartum stillbirths matched 1:3 with live births
- Adjudication process confirmed outcome, date, and gestational age at fetal death
- No association detected by vaccine manufacturer (Moderna aOR 1.00; Pfizer-BioNTech aOR 1.00)
- No association with number of doses or recent vaccination within 6 weeks before stillbirth
The Australian multicenter cohort study 2 provides complementary evidence showing protective associations:
- Vaccinated women had significantly lower stillbirth rates (0.2% vs 0.8%; adjusted OR 0.18,95% CI 0.09-0.37)
- Study included 32,536 births across 12 public maternity hospitals
- 9-month follow-up period from July 2021 to March 2022
- Used inverse propensity score-weighting to adjust for multiple confounders
A 2026 Thai cohort study 3 of 4,032 pregnant women further corroborates these findings, showing vaccination was associated with lower stillbirth rates (aOR 0.41,95% CI 0.16-0.97), with particularly favorable outcomes for second/third trimester vaccination.
Evidence for Tdap Vaccination
While the provided evidence focuses more heavily on COVID-19 vaccines, current guidelines explicitly state there is no evidence of adverse fetal effects from Tdap vaccination 4. The 2026 ACOG guideline notes that "a growing body of data demonstrate the safety" of inactivated vaccines and toxoids during pregnancy 4.
The evidence base for Tdap has accumulated over a longer timeframe than COVID-19 vaccines, with decades of post-marketing surveillance supporting its safety profile. The 2022 WHO/CDC guidelines 5 recommend routine Tdap vaccination with each pregnancy based on this established safety record.
Why This Constitutes "Moderate Strength" Evidence
The evidence quality is considered moderate-to-high strength because:
- Large sample sizes with adequate statistical power to detect rare outcomes like stillbirth
- Rigorous methodology including outcome adjudication 1 and propensity score adjustment 2
- Consistency across multiple populations (U.S., Australia, Thailand) and healthcare systems
- Appropriate comparison groups with careful matching and covariate adjustment
- Follow-up through delivery capturing the complete at-risk period for stillbirth
Important Caveats
- The VSD study 1 had a relatively homogeneous cohort, which may limit generalizability
- Most COVID-19 vaccine data comes from mRNA platforms (Pfizer-BioNTech and Moderna)
- The Australian study 2 showed vaccination uptake was influenced by social determinants of health, suggesting potential selection bias
- "Long-term" in the pregnancy context means follow-up through delivery (approximately 9 months), not years of post-vaccination surveillance
Clinical Bottom Line
Both COVID-19 mRNA vaccines and Tdap are recommended during every pregnancy without concern for increased stillbirth risk 4. The most recent high-quality evidence from 2024-2026 consistently demonstrates either no association or protective associations with stillbirth 1, 2, 3. These findings support current ACOG, CDC, and WHO recommendations for routine maternal immunization 4, 5.